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Abstract
Preclinical studies show that blocking Interleukin–1 (IL–1) retards the progression of Amyo-
trophic Lateral Sclerosis (ALS). We assessed the safety of Anakinra (ANA), an IL–1 recep-
tor antagonist, in ALS patients. In a single arm pilot study we treated 17 ALS patients with
ANA (100 mg) daily for one year. We selected patients with dominant or exclusive lower
motor neuron degeneration (LMND) presentation, as peripheral nerves may be more acces-
sible to the drug. Our primary endpoint was safety and tolerability. Secondary endpoints
included measuring disease progression with the revised ALS functional rating scale
(ALSFRSr). We also quantified serum inflammatory markers. For comparison, we gener-
ated a historical cohort of 47 patients that fit the criteria for enrolment, disease characteris-
tics and rate of progression of the study group. Only mild adverse events occurred in ALS
patients treated with ANA. Notably, we observed lower levels of cytokines and the inflam-
matory marker fibrinogen during the first 24 weeks of treatment. Despite of this, we could
not detect a significant reduction in disease progression during the same period in patients
treated with ANA compared to controls as measured by the ALSFRSr. In the second part of
the treatment period we observed an increase in serum inflammatory markers. Sixteen out
of the 17 patients (94%) developed antibodies against ANA. This study showed that block-
ing IL–1 is safe in patients with ALS. Further trials should test whether targeting IL–1 more
efficiently can help treating this devastating disease.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disorder which affects pri-
marily upper motor neurons in the cortex and lower motor neurons in the brain stem and spi-
nal cord. The disorder leads to complete paralysis and respiratory failure between 3 to 5 years
after symptom onset [1]. Currently there is no effective drug available for ALS; only one
approved drug, riluzole, shows moderate effects on survival but not on muscle strength [2, 3].
Neuroinflammation, consisting of activated microglia and astrocytes as well as infiltrating T
cells, is a common feature in the pathology of ALS [4–7]. Pro- and anti-inflammatory cytokines
and chemokines are increased in serum samples of ALS patients as well as in an ALS mouse
model [6, 8]. Interleukin–1 (IL–1) is a cytokine that plays a central role in regulating inflamma-
tion. IL-1ß, a protein in the IL–1 family, is synthesized as an inactive proform that is proteolyti-
cally activated by caspase–1 in response to various “danger” signals by cytosolic protein
complexes called inflammasomes [9]. Activated caspase–1 is present in cerebral spinal fluid
and spinal cord sections of ALS patients and in a mouse model of ALS [10]. Interestingly, cas-
pase–1 or IL-1ß deficiencies, as well as blocking the IL-1-receptor prolonged the survival but
did not affect the onset of the disease in a mouse model [11, 12]. These data suggest that cas-
pase–1 activation contributes to ALS pathogenesis.
These preclinical studies prompted us to assess the safety and tolerability of Anakinra
(ANA), a recombinant human interleukin-1-receptor antagonist, in ALS patients. ANA has
been approved to treat rheumatoid arthritis [13]. We decided to treat ALS patients with domi-
nant or exclusive lower motor neuron degeneration (LMND) with the rational that inflamma-
tion at peripheral nerve fibres might be more accessible to ANA [14–16] although it was shown
to reach effective concentrations in the CNS [17, 18, 19, 20].
Methods
Study design and participants
Starting in February 2011, we screened patients with LMND and ALS patients diagnosed
according to the revised El Escorial criteria [21] for LMND variants of ALS. All patients under-
went electrophysiology during the diagnosis to rule out inflammatory disorders and to confirm
a degenerative disease. The study was designed as a mono-center, open-label, single-arm pilot
study and was performed at the ALS outpatient clinic of the Charité–University Hospital in
Berlin, Germany. Inclusion criteria were a stable dose of 100 mg riluzole per day for at least 90
days before initiation, a forced vital capacity greater than 50%, disease duration between 6 and
48 months and the ability to provide informed consent. Women of childbearing age were
included if they were not breastfeeding, had a negative pregnancy test and agreed to use birth
control throughout the trial. Patients with current or recurrent infections, significant cardiac
conduction abnormality, hepatic, renal or haematological parameters outside the reference
range or medication with TNF inhibitors were excluded (S1 Table).
Standard protocol approvals, registrations, and patient consents
The ethics review board of the State of Berlin approved this study. The data protection officer
of the Charité consented to the online self-assessment of adverse events and disease progres-
sion using the Internet platform www.ALShome.de. All patients provided written informed
consent and a data safety and monitoring board supervised the study. This trial’s identifier at
ClinicalTrials.gov is NCT01277315.
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Genetic analysis
Patients were genotyped for the two most frequently mutated ALS genes (C9orf72 and SOD1),
which are found to carry mutations in approximately 80% of familial ALS cases in Germany.
Genotyping was performed by Sanger sequencing of all exons (SOD1) or the sequential combi-
nation of fragment length analysis, triple PCR and Southern blotting (C9orf72) as described
recently [22].
Endpoints
The primary endpoints of the study were safety and tolerability of ANA in combination with
riluzole in patients with ALS. Safety was measured by determining adverse and serious adverse
events throughout the one-year treatment period. Tolerability was determined by compliance
(number of ANA dosages provided/number of ANA dosages planned and IL-1RA serum levels
over the 52-weeks treatment period). Secondary endpoints were the number of patients under-
going tracheotomy, invasive assisted ventilation or percutaneous endoscopic gastrostomy, the
number of patients completing the study and the clinical effectiveness as measured by manual
muscle test, revised ALS functional rating scale (ALSFRSr) [23] and forced expiratory vital
capacity. Serum cytokines and inflammatory markers were included as exploratory endpoints.
Procedures
Patients were trained and instructed to inject the daily dose of 100 mg ANA throughout the
study. Patients attended the outpatient clinic at 4, 8, 12, 24, 36 and 52 weeks to undergo a com-
plete neurological examination. Haematological parameters were determined at the laborato-
ries of Labor Berlin, cytokines and chemokines, including IL-1RA, were measured in frozen
serum samples by ELISA or bead-based cytoplex assays by Labor Berlin and the MPIIB.
Data analysis
We characterized the populations using absolute and relative frequencies in categorical vari-
ables. We used mean and standard deviation or median and quartiles for continuous or ordinal
variables. Depending on the scale and distribution, we performed Chi-square tests, t-test or
Mann-Whitney-U test to test for independent variables. We used the paired t-test or Wilcoxon
signed-rank test to assess dependent continuous variables or dependent values with ordinal
scale, such as continuous or ordinal variables at two time points in one group. Due to the
exploratory nature of the study, the calculated p-values were considered exploratory and non-
confirmatory. P-values below 0.05 were regarded statistically significant. Due to some variabil-
ity of patient’s visit times, ALSFRSr values obtained in between the defined visit time points of
4, 8, 12, 24, 36 and 56 weeks were averaged using the midpoint between two time points as cut-
off. Missing ALSFRSr values were multiply imputed (m = 20) using chained equations. Results
were computed in each imputed dataset and were pooled afterwards. We used the commer-
cially available software SAS 9.3 and the free software R 3.1.1 including the package mice to
perform all analyses.
Historical control group
Patients at the Charité ALS outpatient department have excess to an online assessment plat-
form to improve care [24]. The data base includes 2500 patients and we selected those that ful-
filled the inclusion and exclusion criteria of the study group as described at the beginning of
the Methods section. Of the 2500 patients, 866 individuals fulfilled the criteria for enrolment in
our study and were not included in other interventional trials. We only included patients that
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entered self-assessments for at least one year and with a similar regularity than the study
group. To allow a fair comparison to the small number of patients in our cohort, we randomly
selected 47 patients to form the HCG [25]. There were more women in the HCG than in the
study cohort (39% vs 6%) (S2 Table).
Results
We assessed 26 and enrolled 19 patients (17 men/2 women) that fulfilled our inclusion criteria
(Fig 1). Patients were 45 to 72 years old (mean age 57.9 y (SD 7.6) at baseline) and diagnosed
with exclusive LMND or laboratory-supported probable, or definite ALS according to the
revised El Escorial criteria (Table 1) [21] with a dominant LMND. The patients were enrolled
at an early stage with a mean ALSFRSr of 40.7 (SD 3.9) and a moderate disease progression
rate at baseline (mean delta ALSFRSr = 0.35, S2 Table). The disease duration presented a mean
of 22.4 months (SD 8.6). None of the patients had a clinically apparent hypoventilation syn-
drome at baseline.
Two patients dropped out of the trial prematurely: one patient withdrew consent after 4
weeks without serious adverse events (SAE). A second patient suffered from peritoneal abscess
formation after ALS-related percutaneous endoscopic gastrostomy (PEG). ANA treatment was
stopped although this SAE was unlikely to be caused by this drug.
Seventeen patients completed the 52 weeks treatment with full compliance (Table 1). This
was shown by the expected drug demand by the patients and, more reliably, by the consistently
elevated ANA serum levels (S1 Fig).
The patients documented adverse effects weekly online (in total 635 reports) with the verbal
rating scale (VRS) for headache and a Likert scale (0–3) for erythema, swelling, pain and
Fig 1. Study design.
doi:10.1371/journal.pone.0139684.g001
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bleeding at the site of injection. As reported [26], reactions at the site of injection were the
most common adverse effects (Table 2) with a rapid decrease in intensity and frequency during
the course of the trial. Mild headaches were frequently reported (47% of all patients reported
headache at least once). Seven patients had respiratory tract infections, presumably of viral ori-
gin, which cleared without antibiotic therapy. There were three reports of diarrhoea and one
Table 1. Baseline characteristics of all the patients treated with ANA. Abbreviations: ALSFRSr = amyotrophic lateral sclerosis functional rating scale–
revised. LMND = lower motor neuron disease. VC = respiratory viral capacity. UE = upper extremity. LE = lower extremity. n.d. = not determined.





















1 Male 59 36 No 1700 No LE 38 103 98
2 Male 59 25 No - Yes UE 42 91 88
3 Male 51 21 No - Yes UE 44 83 70
4 Male 52 11 No - No LE 38 58 42
5 Male 51 26 No - Yes LE 42 72 49
6 Male 72 15 No - Yes LE 46 101 94
7 Male 69 26 No - No UE 43 89 84
8 Male 49 24 No - Yes LE 38 104 86
9 Male 60 18 No 2400 No UE 43 82 24
10 Male 59 15 No 2000 Yes UE 45 76 52
11 Male 45 36 No - No LE 37 79 66
12 Male 53 18 No n.d. Yes LE 38 83 71
13 Male 59 10 No n.d. Yes LE 38 86 67
14 Male 66 16 No - No UE 47 85 68
15 Female 60 39 No 2300 Yes LE 42 92 111
16 Male 63 27 No - No UE 32 73 47
17 Male 49 18 No - Yes UE 39 66 51
Mean
(SD)





Table 2. Safety profile.
Patients with event Total number of events (% of reports) Degree of severity
Serious adverse events (SAE) mild moderate severe
Abscess formation during PEG 1 (6%)* 1 (0.2%) 0 0 1
Adverse events (AE)
Respiratory tract infection 7 (41%) 11 (1.7%) 2 9 0
Bleeding 12 (70%) 155 (24.4%) 155 0 0
Swelling 12 (70%) 118 (18.6%) 116 2 0
Redness 12 (70%) 81 (12.7%) 71 7 3
Pain 9 (53%) 117 (18.4%) 102 15 0
Headache 8 (47%) 79 (12.4%) 78 1 0
Pain (back/body/shoulder) 3 (18%) 3 (0.5%) 3 0 0
Diarrhoea 2 (12%) 3 (0.5%) 1 2 0
Gastritis 1 (6%) 1 (0.2%) 1 0 0
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case of gastritis that resolved spontaneously. Importantly, we did not observe any new safety
concerns using Anakinra in ALS patients.
Most of the preclinical data rely on ALS caused by point mutations in the SOD1 gene. How-
ever, the majority of ALS cases are sporadic and of unknown etiology with no obvious genetic
association. This heterogeneity might hamper the development of successful therapies. Therefore,
we wanted to determine whether there was a correlation between the response to ANA and a spe-
cific genetic phenotype in our cohort. Fifteen of the patients provided written consent to genotype
mutations in SOD1 and hexanucleotide expansions in C9orf72. We did not identify any missense
mutations in SOD1 but, despite the lack of a family history of ALS [27], found four patients with
a Southern blot confirmed hexanucleotide repeat expansions of 1700 or more repeats in C9orf72.
This is an unexpectedly high representation of 24% in the genotyped subpopulation. The patients
with C9orf72 expansions did not appear clinically distinct from the rest of the cohort. We did not
observe any difference in disease progression or response to ANA based on the patient´s geno-
type. None of the patients in the cohort had a clinically apparent type of dementia.
Our study was designed as an exploratory single-arm trial with the primary outcomes safety
and tolerability; however, to determine whether ANA treatment had an effect on disease pro-
gression, we generated a historical control group (HCG). The 47 individuals of the standard of
care HCG showed similar ALSFRSr, delta ALSFRSr, age and disease duration at baseline com-
pared to the study cohort (S2 Table) except that more women were in the HCG than in the
study cohort (39% vs. 6%). In this cohort we see no difference between men and women
regarding disease progression, duration or age at onset.
The ALSFRSr dropped by 10.76 points (SD 7.1) in the patients treated with ANA over the
52-weeks treatment period (Fig 2). The study cohort showed no overall difference in disease pro-
gression compared to the historical control (first 24 weeks: p = 0.19; 52 weeks p = 0.69; ANCOVA
analysis for group p = 0.164) (Fig 2). Inflammation is reported to correlate with disease progres-
sion [28]; indeed, we observed a relative reduction in the cytokines IL–6 and TNF 24 weeks after
study onset (Fig 3), without reaching statistical significance, probably due to the small group size.
In addition we measured several serummarkers of systemic inflammation [28]. Notably, serum
fibrinogen concentrations decreased from 342.3 (SD 52.6) to 306.2 mg/dl (SD 89.8) after 4 weeks
of ANA treatment. This reduction persisted throughout the trial (Fig 3; p< 0.01).
In contrast, several cytokines increased between weeks 24 and 52, suggesting secondary inef-
fectiveness of the treatment in the latter half of the study period (Fig 3C). C-reactive protein
(CRP) levels were low at baseline and increased significantly towards the end of the study
period (Fig 3D) [28]. The average expiratory vital capacity decreased from 83.7% (SD 12.6) at
baseline to 68.7% (SD 22.9) at the end of the trial.
Remarkably, 16 out of 17 patients (94%) generated IgG antibodies against ANA as measured
by ELISA (S2 Fig). We confirmed by SDS gel electrophoresis and mass spectrometry that com-
mercially available ANA, which we used both for the patients and for the ELISA, was pure
(S2B Fig). Most patients developed anti-ANA antibodies after only four weeks of treatment
and the titers remained high throughout the study (S2C Fig).
Discussion
Inflammation has been described both in patients and animal models of ALS, but its role in
ALS pathogenesis remains incompletely understood [6]. Based on preclinical studies, we pro-
posed that the activation of caspase–1 and the production of IL–1 contributed to disease pro-
gression [11, 12].
Here we report that ANA in combination with riluzole in ALS patients with LMND is safe
and well tolerated. This is consistent with previous reports from patients with rheumatoid
Anakinra in ALS
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Fig 2. ALS disease progression. Absolute values (A) and changes from baseline (B) in ALSFRSr total score during the 12 months study period comparing
the group of patients treated with ANA and the historical control.
doi:10.1371/journal.pone.0139684.g002
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Fig 3. Inflammatory serum parameters. Serum concentrations of the inflammatory cytokines IL–6 (A) and TNF (B) as well as the and hepatic acute phase
proteins fibrinogen (C) and C-reactive protein (D) in all the patients included in the study.
doi:10.1371/journal.pone.0139684.g003
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arthritis [29]. In ALS patients this observation is of special interest, since they are prone to
respiratory tract infections due to hypoventilation and aspiration [1, 30, 31]. We observed no
new safety concerns for the use of ANA in this patient cohort. Our data show that ANA is well
tolerated and can be considered safe in ALS patients.
This pilot study was not designed to detect significant differences in efficacy nor was it suffi-
ciently powered. However, we observed serum fibrinogen, which is elevated in ALS patients
[28], to be reduced upon ANA treatment. However, reduction of inflammatory cytokines like
IL–6 and TNF did not reach statistical significance after six months of treatment.
Since most of the patients generated anti-ANA antibodies, it is possible that they blocked
ANA and abrogated clinical effectiveness. Indeed, neutrophil numbers (S3 Fig) and inflamma-
tory cytokine levels (especially IL–6 and TNF) increased between weeks 24 and 52, suggesting
that ANA was no longer effective. The incidence of anti-ANA antibodies here is higher than
reported previously [32] [33]. We do not know whether the incidence of antibodies against
ANA is underreported in the literature. It was been reported that only a subfraction of anti-
ANA antibodies have blocking effects in cell culture, but we assume that any specific antibody
titer effects either pharmacokinetics or pharmakodynamics in vivo, especially related to perme-
ation of the blood-brain-barrier.
We propose that targeting IL–1 induced inflammation leads to a reduction in IL–1 mediated
inflammation. IL–1 is produced mainly by monocytes and macrophages as well as microglia. It
drives the production of IL–6 and exacerbates inflammation. The local production of IL–1 may
affect peripheral nerves. We recruited LMND patients based on the hypothesis that they partic-
ularly benefit from bioavailable ANA at the peripheral part of lower motor neurons. Neverthe-
less, ANA might achieve effective concentrations in the CNS by passive transport across the
blood-brain-barrier under steady state and disease conditions [14, 15].
Previous attempts to diminish inflammation with cyclooxygenase–2 (COX) inhibitors [34,
35], minocycline [36, 37], sodium chlorite [38], interferon-beta [39] and thalidomide [40, 41]
did not show beneficial effects on ALS progression. It is important to note that this trial
included only patients with LMND and also that we started the treatment relatively early after
disease onset (median ALSFRSr of 41.6; SD 3.1) [42]. This also means that larger and more het-
erogeneous patient groups with ALS need to be tested before recommending anti-IL1 for
broader groups of patients. The pilot study was subject to the inherent limitations of (1) a small
number of patients precluding robust statistical analysis of the data, (2) analysis of inflamma-
tory parameters in serum but not in CSF and (3) lacking a double-blinded placebo control
group and using a historical control group instead.
In summary, our results suggest that IL–1 may serve as a pharmacological target for ALS-
related inflammation; however, it remains an open question whether this leads to slower dis-
ease progression. Given the proven safety and tolerability of ANA in ALS, follow-up trials suffi-
ciently powered to determine efficacy are justified. The generation of anti-ANA antibodies is a
challenging problem; alternatively higher ANA dosage or a different route of application (e.g.
intravenous or intrathecal) (14–16) could be useful. Peripheral inflammatory mediators, like
cytokines, might provide the basis for futility design studies to assess anti-inflammatory drug
candidates in ALS.
Supporting Information
S1 Fig. Interleukin-1RA serum concentration in all the patients that participated in the
study. Plotted are individual values, median. High values are capped at 1,3x105 pg/ml.
(TIF)
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S2 Fig. Patients treated with ANA develop anti-ANA antibodies. (A) Coomassie-blue stain
of SDS-PAGE of commercially available ANA demonstrating the purity of the material. The
identity of the protein was confirmed by mass spectrometry. (B) Anti-ANA titrations for each
patient (measured colorimetrically by ELISA) before and after treatment with ANA. On the
right shows the patient number sera that are also tested in “C” (C) Commercially available
ANA was resolved by SDS-PAGE, transferred to a membrane and blotted with patients’ sera.
None of the sera recognized ANA before treatment and three of the patients (11, 14 and 5)
developed antibodies specific to ANA. (D) ELISA titrations for each of the patients during the
study. The titers of anti-ANA antibodies increased during the treatment (except for patient 4).
(TIF)
S3 Fig. Blood cell counts of all study patients treated with ANA. Counts for neutrophils (A),
erythrocytes (B), thrombocytes (C) and eosinophils (D) for all the patients included in the
study treated with ANA. Plotted are individual counts, median.
(TIF)
S1 Table. Inclusion and exclusion criteria for eligibility in this study.  According to the
revised El Escorial Criteria.
(DOC)
S2 Table. Baseline characteristics of the patients included in the historical control and the
treated cohort. Data are mean (SD) or n (%). ALSFRSr = Amyotrophic lateral sclerosis func-
tional rating scale–revised. d/eLMND = dominant/exclusive lower motor neuron degeneration.
(DOC)
S1 File. Original study protocol (German).
(PDF)
S2 File. Translated study protocol (English).
(PDF)
S3 File. TREND checklist.
(PDF)
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